- Category: Drug Advisories & Warnings
- Published on Friday, 23 October 2015 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) issued a warning this week that recently approved interferon-free therapy for hepatitis C virus (HCV) infection can produce serious liver damage, mainly in people who already have advanced liver disease. The warning applies to AbbVie's paritaprevir/ritonavir/ombitasvir coformulation, which is sold alone as Technivie for the treatment of HCV genotype 4, and as part of the Viekira Pak regimen for HCV genotype 1; in Europe the latter regimen is sold as separate components, Viekirax and Exviera.